
    
      Open label phase I, dose escalation trial for patients with triple negative inflammatory,
      loco-regional advanced or metastatic breast cancer either inoperable after neoadjuvant
      chemotherapy or operated with residual disease (after neoadjuvant chemotherapy).
    
  